BACKGROUND: Despite the recent therapeutic advances, approximately one-third of patients with chronic migraine fail to achieve clinically meaningful benefit, and existing oral preventive therapies remain limited by tolerability and off-target effects. There is, therefore, a pressing need for new, well-tolerated, mechanistically distinct preventive treatments for chronic migraine. This hypothesis article evaluates the pharmacological and biological rationale supporting guanfacine as a potential…
